Literature DB >> 10433161

Calcium use increases risk of calciphylaxis: a case-control study.

J M Zacharias1, B Fontaine, A Fine.   

Abstract

OBJECTIVE: To investigate the risk factors for the development of calciphylaxis in renal failure, a poorly understood and often fatal condition characterized by calcium deposition in tissues.
DESIGN: Retrospective case-control study.
SETTING: University hospital peritoneal dialysis center. PATIENTS: Eight continuous ambulatory peritoneal dialysis (CAPD) patients with calciphylaxis were identified in a 3-year period. We matched up to five controls for dialysis modality and length of time on dialysis with each case. STATISTICS: Multivariate conditional logistic regression analysis for matched case-controls. MAIN OUTCOME MEASURES: Laboratory data and demographics were collected as well as cumulative calcium and vitamin D ingestion over the year prior to disease onset.
RESULTS: All the patients were female, versus only 38% (14/37) of controls (p < 0.0001). While not statistically significant, a majority of the patients were diabetic [62.5% (5/8) vs 32% (12/37)]. Peak and average levels of serum calcium, phosphate, calcium x phosphate product, parathyroid hormone (PTH), albumin, iron, total iron-binding capacity (TIBC), and ferritin were not significantly different in cases compared with controls. The use of calcitriol alone or with calcium carbonate was not found to be a significant risk factor for the development of calciphylaxis. In a multivariate analysis, iron intake seemed to be protective, contrary to previous reports, while the use of calcium carbonate was associated with a strong trend to increased risk of calciphylaxis development (odds ratio = 1.029/g and 1.011/g calcium ingested per month, at 1 and 2 - 3 months prior to calciphylaxis development; p = 0.0556 and 0.0565, respectively).
CONCLUSION: These data, although limited by the small numbers of index cases, suggest that calcium ingestion is a risk factor for calciphylaxis. The increased use of calcium salts as a phosphate binder in recent years might explain the apparent increased incidence of calciphylaxis in our and other centers. The preponderance of female diabetics among cases reported elsewhere was confirmed in our study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433161

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  11 in total

Review 1.  Calciphylaxis: from the disease to the diseased.

Authors:  Tiago M Oliveira; João M Frazão
Journal:  J Nephrol       Date:  2015-04-03       Impact factor: 3.902

2.  Fatal calciphylaxis in two patients with giant cell arteritis.

Authors:  K Brouns; E Verbeken; H Degreef; H Bobbaers; D Blockmans
Journal:  Clin Rheumatol       Date:  2006-07-27       Impact factor: 2.980

3.  Painful skin ulcers in a hemodialysis patient.

Authors:  Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 8.237

4.  A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

Authors:  Sagar U Nigwekar; Sophia Zhao; Julia Wenger; Jeffrey L Hymes; Franklin W Maddux; Ravi I Thadhani; Kevin E Chan
Journal:  J Am Soc Nephrol       Date:  2016-04-14       Impact factor: 10.121

Review 5.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

6.  Metal deposition in calcific uremic arteriolopathy.

Authors:  Lavanya Amuluru; Whitney High; Kim M Hiatt; James Ranville; Sudhir V Shah; Bilal Malik; Sundararaman Swaminathan
Journal:  J Am Acad Dermatol       Date:  2009-04-29       Impact factor: 11.527

7.  Treatment of severe metastatic calcification and calciphylaxis in dialysis patients.

Authors:  Saurabh K Goel; Keith Bellovich; Peter A McCullough
Journal:  Int J Nephrol       Date:  2011-02-24

8.  Calcific uremic arteriolopathy in peritoneal dialysis populations.

Authors:  Nicholas New; Janaki Mohandas; George T John; Sharad Ratanjee; Helen Healy; Leo Francis; Dwarakanathan Ranganathan
Journal:  Int J Nephrol       Date:  2011-06-27

9.  A new paradigm for the treatment of secondary hyperparathyroidism.

Authors:  Angel L M de Francisco; Fernando Carrera
Journal:  NDT Plus       Date:  2008-01

10.  Calciphylaxis associated with chronic kidney disease and low bone turnover: management with recombinant human PTH-(1-34).

Authors:  Grahame Elder; Karthic S Kumar
Journal:  NDT Plus       Date:  2008-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.